Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Eisai Co. Ltd (OP: ESALF ) 43.25 +4.13 (+10.56%) Streaming Delayed Price Updated: 11:05 AM EDT, Jun 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 117 Open 43.25 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 39.12 Today's Range 43.25 - 43.25 52wk Range 37.53 - 70.40 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Why Is Eli Lilly Stock Trading Higher Premarket Tuesday? June 11, 2024 Shares of Eli Lilly surged as an FDA advisory committee endorsed donanemab, an Alzheimer's treatment shown to significantly impact early-stage patients. The drug's benefits outstripped risks, setting... Via Benzinga Exposures Product Safety European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab March 22, 2024 Biogen and Eisai face delays as EMA postpones the oral explanation for the lecanemab review. Procedural issues at EMA prompt setback, impacting drug evaluation process amid recent EU court ruling. Via Benzinga Performance YTD -12.86% -12.86% 1 Month +2.00% +2.00% 3 Month +3.76% +3.76% 6 Month -13.06% -13.06% 1 Year -34.74% -34.74% More News Read More Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer December 08, 2023 Via Benzinga Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage October 13, 2023 Via Benzinga LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly October 10, 2023 Via Benzinga Current Analysis: Eisai Co Ltd (ESAIY) July 16, 2023 Via Talk Markets Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories September 25, 2023 Via Benzinga Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi September 25, 2023 Via Benzinga Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer September 22, 2023 Via Benzinga Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial August 25, 2023 Via Benzinga Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts July 07, 2023 Via Benzinga Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources June 13, 2023 Via Benzinga Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote June 12, 2023 Via Benzinga Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable' June 08, 2023 Via Benzinga FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval June 08, 2023 Via Benzinga Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen May 04, 2023 Via Benzinga Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes! April 21, 2023 Via Benzinga Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer April 10, 2023 Via Benzinga National Institute on Aging Aims Building $300M Alzheimer's Research Database April 03, 2023 Via Benzinga Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug March 31, 2023 Via Benzinga Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments March 16, 2023 Via Benzinga Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity March 14, 2023 Via Benzinga Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment March 06, 2023 Via Benzinga The 7 Best Growth Stocks to Buy for February 2023 February 06, 2023 Via InvestorPlace FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway January 06, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
